Related Experiment Video
Updated: Jan 9, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Experimental study on polysaccharide of Cipangopaludina chinensis against HBV in vitro]
Xiao-Yan Liu1, Chao-Pin Li, Ke-Xia Wang
1School of Medicine, Anhui University of Science & Technology, Huainan 232001, China.
Objective:
To evaluate the biological activity of polysaccharide of Cipangopaludina chinensis (PCC) against HBV in vitro.
Method:
HepG2 2. 2. 15 cells were taken as the in vitro experimental model. The cell toxicity was observed by MTT. PCC of different safe concentrations and positive control medicine 3TC were added into the cells. Cell control without medicine was set at the same time. Cultural supernatants were collected at 9 d. HBsAg and HBeAg in cultural supernatants were tested by ELISA. The content of HBV-DNA was detected by TaqMan probe fluorescence quantitative PCR.
Result:
TC0 and TC50 of PCC in HepG2 2. 2. 15 cell culture were 1 g . L-1 and >10 g . L-1, respectively, suggesting low toxicity in cells. IC50 of PCC in HepG2 2. 2. 15 cells HBsAg and HBeAg were 0. 501, 0. 401 g. L-1, with SI being >19.96 and >24. 94, respectively. PCC could effectively inhibit the secretion of HBsAg and HBeAg, and have a better effect on HBeAg than on HBsAg. PCC had a significant inhibitory effect on HBV-DNA in HepG2 2. 2. 15 cells at concentrations of 0. 1, 1 g . L-1 P <0.05).
Conclusion:
PCC has the effect against HBV activity in vitro to some extent, with low toxicity, thereby having a good prospect for application.
